Annette von Drygalski

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Activated superFactor V (superFVa) is a novel engineered FV with excellent prohemostatic efficacy. SuperFVa has three APC cleavage site mutations and an interdomain disulfide bond. Stability, pharmacokinetics, and immunogenic and thrombogenic potential are reported here. Stability and circulating half-life were determined after incubation in buffer and(More)
Background. The etiology of the high prevalence of hypertension among patients with hemophilia (PWH) remains unknown. Methods. We compared 469 PWH in the United States with males from the National Health and Nutrition Examination Survey (NHANES) to determine whether differences in cardiovascular risk factors can account for the hypertension in hemophilia.(More)
OBJECTIVE An increased risk of bleeding is observed in patients receiving activated protein C (APC), which may be a limiting factor for the application of novel APC therapies. Since APC's therapeutic effects often require its cytoprotective activities on cells but not APC's anticoagulant activities, an agent that specifically antagonizes APC's anticoagulant(More)
  • 1